Paul Audhya
Directeur Technique/Scientifique/R&D chez KALVISTA PHARMACEUTICALS, INC.
Fortune : 737 709 $ au 30/04/2024
Postes actifs de Paul Audhya
Sociétés | Poste | Début | Fin |
---|---|---|---|
KALVISTA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 03/05/2021 | - |
Historique de carrière de Paul Audhya
Anciens postes connus de Paul Audhya
Sociétés | Poste | Début | Fin |
---|---|---|---|
ARENA PHARMACEUTICALS | Corporate Officer/Principal | 26/11/2018 | 01/03/2021 |
VERTEX PHARMACEUTICALS INCORPORATED | Directeur Technique/Scientifique/R&D | 01/02/2016 | 01/09/2018 |
HOSPIRA, INC. | Directeur Technique/Scientifique/R&D | 01/06/2013 | 01/02/2016 |
REATA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 04/07/2011 | - |
Formation de Paul Audhya
New York University | Undergraduate Degree |
Pepperdine University | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 8 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 4 |
Undergraduate Degree | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 6 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
KALVISTA PHARMACEUTICALS, INC. | Health Technology |
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
Entreprise privées | 3 |
---|---|
Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Hospira, Inc.
Hospira, Inc. Pharmaceuticals: MajorHealth Technology Hospira, Inc. provides injectable drugs and infusion technologies. It offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services. The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL. | Health Technology |
- Bourse
- Insiders
- Paul Audhya
- Expérience